Krishnan, Amrita
Kapoor, Prashant
Palmer, Joycelynne M.
Tsai, Ni-Chun
Kumar, Shaji http://orcid.org/0000-0001-5392-9284
Lonial, Sagar
Htut, Myo
Karanes, Chatchada
Nathwani, Nitya
Rosenzweig, Michael
Sahebi, Firoozeh
Somlo, George
Duarte, Lupe
Sanchez, James F.
Auclair, Daniel
Forman, Stephen J.
Berdeja, Jesus G.
Article History
Received: 12 September 2017
Revised: 17 November 2017
Accepted: 24 November 2017
First Online: 23 February 2018
Compliance with Ethical Standards
:
: Dr. Krishnan serves on the speakers’ bureau for Janssen, Celgene, Takeda, and Onyx, is a consultant for Janssen and Celgene, and has stock ownership in Celgene. Dr. Kapoor is a principal investigator on studies funded by Takeda, Celgene, and Amgen. Dr. Kumar has participated in advisory boards for Takeda, Celgene, Amgen, Janssen, Abbvie, Merck, and SkylineDX, and receives clinical trial funding from Takeda, Janssen, Abbvie, Merck, Celgene, Sanofi, Roche, and Sanofi. Dr. Lonial is a consultant for Millennium, Celgene, Novartis, BMS, Onyx, and Janssen. Dr. Karanes has research funding from Celgene. Dr. Rosenzweig serves on the speakers’ bureau for Celgene. Dr. Somlo serves on the speakers’ bureau for Takeda, is a consultant for Pfizer, AstraZeneca, Abbvie, Puma, Novartis, and Celgene, and receives research support from Merck, Celgene, and Genentech. Dr. Forman has license agreements with and receives research support from Mustang Therapeutics Inc. Dr. Berdeja has received institutional funding from Takeda, Teva, Celgene, Acetylon, MEI, BMS, Amgen, Janssen, Novartis, Abbvie, Curis, Array, Constellation, and Bluebird Bio. The remaining authors declare no competing financial interests.